WallStSmart

Cosmos Health Inc. (COSM)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 21949% more annual revenue ($13.18B vs $59.79M). HSIC leads profitability with a 3.0% profit margin vs -31.0%. HSIC earns a higher WallStSmart Score of 56/100 (C).

COSM

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.37

HSIC

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 8.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

HSICUndervalued (+12.5%)

Margin of Safety

+12.5%

Fair Value

$93.39

Current Price

$74.25

$19.14 discount

UndervaluedFair: $93.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
37.9%10/10

Revenue surging 37.9% year-over-year

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

COSM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$16.65M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-63.8%2/10

ROE of -63.8% — below average capital efficiency

HSIC3 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 37.9% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while HSIC is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.47 — expect wider price swings.

COSM is growing revenue faster at 37.9% — sustainability is the question.

HSIC generates stronger free cash flow (338M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (56/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?